Ileal bile acid transporter (IBAT) inhibitors may emerge as a treatment option for cholestatic liver disease. Therefore, understanding how they work and their effects on the body is crucial in managing patients with hepatic and metabolic disorders. In this video, Professor Paul A. Dawson, a paediatric GI, hepatology and nutrition professor at the Emory University School of Medicine, explains the mechanism of action of IBAT inhibitors and their physiological effects on cholestatic liver disease and metabolic disease.
This independent educational activity is supported by an educational grant from Albireo. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Albireo Pharmaceuticals have had no influence on the content of this education.
